^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Cutaneous Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    J Clin Oncol
    Published date:
    03/31/2020
    Excerpt:
    Recommendation 3.2….For patients with BRAF-mutant (V600) unresectable/metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order)...dabrafenib plus trametinib…
    DOI:
    10.1200/JCO.20.00198
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Title:

    trametinib (Mekinist®) is accepted for restricted use within NHSScotland.

    Excerpt:
    trametinib (Mekinist) is accepted for restricted use within NHSScotland....in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

    Excerpt:
    ...Histologically confirmed acral lentiginous or cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and BRAF V600 mutation-positive. The test was to have been conducted at a designated central laboratory...
    Trial ID:
    NCT02083354
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma

    Published date:
    06/10/2020
    Excerpt:
    Overall, 77 patients of East Asian origin (including 61 from Mainland China) with unresectable or metastatic BRAF V600-mutant cutaneous melanoma were enrolled....ORR was 61% (95% confidence interval: 49.2-72.0), with four patients (5%) achieving complete response. Median DOR and PFS were 11.3 and 7.9 months, respectively....These results support the efficacy and tolerability of dabrafenib in combination with trametinib in East Asian patients with unresectable or metastatic BRAF V600-mutant cutaneous melanoma.
    DOI:
    10.1016/j.ejca.2020.04.044
    Trial ID:
    NCT02083354